Loading...
At this year's meeting of the American Society of Clinical Oncology (ASCO 2020), held virtually May 29–31, investigators discussed the latest findings in cancer research. Here, Associate Editor Michael E. Williams, MD, ScM, reviews key presentations on new treatments for patients with multiple myeloma, classical Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. All meeting abstracts can be viewed in the ASCO meeting library.
Triple-drug regimens including an immunomodulatory agent plus a proteasome inhibitor are a standard for the initial treatment of patients with multiple myeloma. Kumar and colleagues reported results of the prospective, multicenter, r…